T-Cell Engagers In Multiple Myeloma: A Clinical Review

Ahmad Al-Jarrad, Samhar Samer Alouch, Yogesh Chawla, Wilson I Gonsalves Division of Hematology, Mayo Clinic, Rochester, MN, USACorrespondence: Wilson I Gonsalves, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA, Tel +1 507-284-2511, Email [email protected]: T-cell engagers (TCEs) are engineered to bind both the CD3 subunit on T-cells and specific antigens on tumor cells, triggering T-cell activation and tumor cell lysis. TCEs targeting B-cell maturation antigen (BCMA) and G-protein-coupled receptor, class C, group 5, member D (GPRC5D) have demonstrated significant clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). As a monotherapy, TCEs have had overall response rates (ORRs) of over 60%, with deep and durable hematological responses. Common toxicities include cytokine release syndrome (CRS), infections, and on-target off-tumor effects. Ongoing research looks to enhance the efficacy and tolerability of TCEs for the next generation of products to play an even bigger role in treating patients with MM.Keywords: T-cell engagers, multiple myeloma, BCMA, GPRC5D